Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.87 |
| ▸ | KDR | P35968 | 2/20 | 0.85 |
| ▸ | FBP1 | P09467 | 2/20 | 0.85 |
| ▸ | AURKA | O14965 | 1/20 | 0.85 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.85 |
| ▸ | INSR | P06213 | 1/20 | 0.85 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.85 |
| ▸ | FLT4 | P35916 | 1/20 | 0.85 |
| ▸ | CLK1 | P49759 | 1/20 | 0.85 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.85 |
| ▸ | TEK | Q02763 | 1/20 | 0.85 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30520472 | 1.00 | EGFR (0.87) | EGFRKDRFBP1AURKAERBB2 | |
| SCHEMBL14092460 | 0.95 | EGFR (0.92) | EGFRKDRFBP1AURKAERBB2 | |
| SCHEMBL13529196 | 0.94 | EGFR (0.98) | EGFRKDRFBP1AURKAERBB2 | |
| SCHEMBL30207668 | 0.93 | EGFR (0.85) | EGFRKDRFBP1AURKAERBB2 | |
| SCHEMBL28520911 | 0.93 | EGFR (0.85) | EGFRKDRFBP1AURKAERBB2 | |
| SCHEMBL31491085 | 0.93 | EGFR (0.85) | EGFRKDRFBP1AURKAERBB2 | |
| SCHEMBL5412843 | 0.93 | EGFR (0.84) | EGFRKDRFBP1AURKAERBB2 | |
| SCHEMBL14863005 | 0.93 | EGFR (0.84) | EGFRKDRFBP1AURKAERBB2 | |
| SCHEMBL28907231 | 0.93 | EGFR (0.84) | EGFRKDRFBP1AURKAERBB2 | |
| SCHEMBL14964773 | 0.93 | EGFR (0.85) | EGFRKDRFBP1AURKAERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193242-A1 | IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-23 | — | — | US | disclosed |
| WO-2020163598-A1 | IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-08-13 | — | — | WO | disclosed |
| US-9233995-B2 | Quinazoline derivatives and quinazoline complex protein kinase inhibitor for inhibiting multiplication of tumor cells and preparation method thereof | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-01-12 | — | — | US | disclosed |
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCE (CN) | 2013-08-29 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-7645747-B2 | Improved pharmacokinetic properties, oral bioavailability; side effect reduction | GILEAD SCIENCES, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | CANNIZZARO CARINA | 2009-07-16 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-20070281907-A1 | Kinase Inhibitor Phosphonate Conjugates | GILEAD SCIENCES, INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193242-A1 | IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF | CD74, CD2BP2, SERPINB1 | EGFR 3898/4885KDR 3287/4885FBP1 2209/4885 |
| US-20090181930-A1 | KINASE INHIBITORY PHOSPHONATE ANALOGS | PIK3CA, PNKP, PIK3CB | EGFR 802/4885KDR 860/4885FBP1 522/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | EGFR 493/4885KDR 1628/4885FBP1 132/4885 |
| US-20070281907-A1 | Kinase Inhibitor Phosphonate Conjugates | PIK3CA, PNKP, PLK1 | EGFR 498/4885KDR 593/4885FBP1 589/4885 |
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | MAP3K21, MAP3K15, MAP3K14 | EGFR 225/4885KDR 2894/4885FBP1 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.